source
- 'Still a bull': Novo's CEO on honoring heritage and planning for the future amid corporate rebrandNovo CEO Mike Doustdar—tapped to breathe new life into the Danish drugmaker last year after losing GLP-1 marketing ground to chief rival Eli Lilly—isn’t one to make changes for the sake of change.
- Senators probe nominee Chris Klomp’s influence on HHS health-policy and drug pricingSenators on the Finance and Energy committees held two days of hearings to examine the authority that Chris Klomp would have if confirmed as deputy secretary of HHS. Klomp, a senior adviser who se…